Sandro Pignata

Quality of life: gynaecological cancers.

S. Pignata, G. Scambia, E. Ballatori, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemotherapy-free treatments: are we ready for prime time?

S. Pignata, D. Lorusso, A. González-Martín, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.

D. Timmerman, J. Ledermann, R. Glasspool, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study.

D. Provencher, J. Ledermann, M. Birrer, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial.

V. Gebski, E. Eisenhauer, M. Brundage, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study with weekly cisplatin-paclitaxel and concurrent radiotherapy in patients with carcinoma of the cervix uteri.

S. Pignata, F. Iodice, P. Ricchi, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives

D. Califano, C. Pisano, S. Cecere, 2020 .

PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives

D. Califano, P. Panici, C. Pisano, 2020 .